; and (3) ensure coordination of efforts to identify, disseminate, and evaluate best practices related to— (A) improving the capacity of, and access to, recovery support services; and (B) supporting the training, education, professional development, and retention of peer support specialists. (c) Report Not later than 4 years after the date of enactment of the SUPPORT for Patients and Communities Reauthorization Act , the Assistant Secretary for Mental Health and Substance Use shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the activities conducted by the Office, including— (1) a description of the specific roles and responsibilities of the Office; (2) a description of the relationship between the Office and other relevant components or programs of the Substance Abuse and Mental Health Services Administration; (3) the identification of any gaps in the activities of the Substance Abuse and Mental Health Services Administration or challenges in coordination between the Office and such relevant components or programs of such agency; and (4) recommendations related to the continued operations of the Office. (d) Sunset This section shall cease to have force or effect on September 30, 2028. . IV Technical amendments 401. Delivery of a controlled substance by a pharmacy to an administering practitioner Section 309A(a) of the Controlled Substances Act ( 21 U.S.C. 829a(a) ) is amended by striking paragraph (2) and inserting the following: (2) the controlled substance is a drug in schedule III, IV, or V to be administered— (A) by injection or implantation for the purpose of maintenance or detoxification treatment; or (B) intranasally, subject to risk evaluation and mitigation strategy pursuant to section 505–1 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355–1 ), with post-administration monitoring by a health care professional